Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.
Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.
The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.
Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.
Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.
This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.
Can-Fite BioPharma Ltd. (NYSE: CANF) has signed a definitive agreement with a healthcare-focused institutional investor to sell 5,000,000 American Depositary Shares (ADSs) at $2.00 each, raising gross proceeds of $10 million for research, development, and working capital. A concurrent private placement of warrants to purchase up to 5,000,000 ADSs will also occur at the same price. The offering, expected to close around August 16, 2021, is facilitated by H.C. Wainwright & Co. The ADSs are offered under a shelf registration statement filed with the SEC.
Can-Fite BioPharma Ltd. (NYSE American: CANF) has appointed Yossi Borenstein as an External Director during its recent annual general meeting. Borenstein, CEO of Shizim Group and a veteran in the Israeli biomed industry, brings over 35 years of experience, having previously managed Bristol-Myers Squibb (Israel) and served in various leadership roles across multiple organizations. Can-Fite, engaged in developing therapies for cancer, liver, and inflammatory diseases, continues its clinical progress with drug candidates like Piclidenoson and Namodenoson.
Can-Fite BioPharma Ltd (NYSE: CANF) has completed preparatory work for its pivotal Phase III trial of Namodenoson, targeting hepatocellular carcinoma (HCC), the most prevalent liver cancer. The trial will enroll 450 patients globally and is designed to assess overall survival and safety. Both the FDA and EMA have agreed to the trial protocol, and Namodenoson has received Orphan Drug and Fast Track designations. This advancement comes amid a global market for HCC treatments projected to reach $3.8 billion by 2027.
Can-Fite BioPharma (NYSE: CANF) has entered a development and commercialization agreement with Vetbiolix for its drug, Piclidenoson, targeting osteoarthritis in pets. Vetbiolix will conduct proof-of-concept studies over two years, covering all associated costs, and may obtain a license for further development if the data is positive. The canine osteoarthritis market is projected to reach $3 billion by 2024, with the broader companion animal health market expected to grow to $27 billion by 2028. Piclidenoson offers a potentially effective oral treatment alternative to existing NSAIDs.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced that the Chinese National Intellectual Property Administration granted a Notice of Allowance for its patent on an A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation. This patent supports their liver drug candidate, Namodenoson, which is set to enter Phase IIb trials for non-alcoholic steatohepatitis (NASH) in Q3 2021, following successful Phase IIa results. Namodenoson has been licensed in China with potential milestone payments of up to $74.5 million. The NASH market in China is projected to reach $6.4 billion by 2027.
Can-Fite BioPharma Ltd (NYSE American: CANF) received clearance from the Israeli Ministry of Health to initiate a Phase IIb study of its drug candidate Namodenoson for treating NASH. Enrollment is expected to start in Q3 2021, earlier than previously anticipated. The study aims to assess Namodenoson's efficacy in 140 subjects, comparing its effects against a placebo over 36 weeks. Given the urgent unmet medical need for NASH treatments, the market for NASH pharmaceuticals could reach $35-40 billion by 2025.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announces that Dr. Sari Fishman will present at the BIO Digital Convention on June 10-11 & 14-18, 2021. Can-Fite has secured approximately $20 million from out-licensing agreements for its drug candidates, with potential milestone payments of up to $130 million. The company anticipates key developments, including topline data from Phase III psoriasis and Phase II COVID-19 trials, as well as initiating pivotal trials in liver cancer and NASH by year-end.
Can-Fite BioPharma Ltd (NYSE American: CANF) reported its financial results for Q1 2021, revealing revenues of $0.15 million, down 25.2% from $0.20 million in Q1 2020. The company secured a $42.7 million out-licensing deal with Ewopharma, including $2.25 million upfront and up to $40.45 million contingent on milestones. The Phase III Comfort™ psoriasis study reached 75% enrollment, with topline results anticipated in Q4 2021. Can-Fite’s R&D expenses declined by 65.5% to $1.30 million, while general and administrative expenses rose to $1.01 million. Future trials for liver cancer and NASH are set for late 2021.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will appear on The RedChip Money Report on May 29th, at 7 p.m. local time, reaching 73 million homes in the U.S. The interview will cover upcoming milestones and updates on Can-Fite's drug pipeline, including Piclidenoson and Namodenoson, which target conditions like psoriasis and liver cancer. Piclidenoson is in Phase III trials for psoriasis and Phase II studies for COVID-19, while Namodenoson has shown promise in treating liver cancer and has received Orphan Drug Designation.
Can-Fite BioPharma Ltd (NYSE American: CANF) will present at Benzinga’s Global SmallCap Conference on May 13, 2021. CEO Dr. Pnina Fishman will discuss the company’s advancements in treating psoriasis, liver cancer, and NASH. Can-Fite's drug candidates are in Phase II and Phase III trials, showcasing clinical proof of concept. The company’s lead drug, Piclidenoson, targets moderate COVID-19, while Namodenoson is set for Phase III for hepatocellular carcinoma and has received Orphan Drug and Fast Track Designation from the FDA.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What does Can-Fite BioPharma Ltd. specialize in?
Where is Can-Fite BioPharma Ltd. located?
What is Piclidenoson?
What is Namodenoson used for?
What stage are the trials for Namodenoson?
What is the A3 adenosine receptor (A3AR)?
How does Can-Fite BioPharma's technology benefit patients?
What is the significance of Can-Fite BioPharma's partnerships?
Is Can-Fite BioPharma listed on any stock exchange?
What is the focus of Can-Fite BioPharma's current projects?
